ValiRx Plc is an investment holding Company. The Company is engaged in developing technologies and products in oncology therapeutics and diagnostics. The Company operates in two segments: drug development and the sale of self-test drug kits. The Company is also engaged in developing a groundbreaking class of therapeutics based on the GeneICE platform and hypergenomics technology. The Company�s subsidiaries include ValiRx Bioinnovation Limited, which is the holding company, ValiPharma Limited, which is engaged in the therapeutic research and development; ValiMedix Limited, which is a medical diagnostics company and ValiRx Finland OY, which is engaged in therapeutic research and development. On August 18, 2011, the Company acquired ValiRx Finland OY. On January 5, 2012, the Company acquired Pharmatest Services Oy.